Novo v. Lilly: The False-Advertising Fight Over Zepbound/Mounjaro Ads — PI Motion Pending
Novo's false-advertising suit against Lilly (filed late July 2026, U.S. District Court for the District of New Jersey) escalated quickly: per a Reuters report relayed by Stocktwits on Jul 24, 2026, "Novo Nordisk is seeking a preliminary U.S. court injunction to immediately block Lilly's advertisements for Zepbound and Mounjaro." Novo also wants "a permanent injunction requiring Lilly to withdraw the campaigns and publish corrective advertisements."
The alleged deceptions are dose-comparison framing: "Lilly's Zepbound advertisements compare the drug's highest approved dose with lower doses of Wegovy while excluding Wegovy's newer 7.2 mg dose, which received U.S. Food and Drug Administration (FDA) approval in March 20261," and "Novo argued that no head-to-head clinical trial has compared the highest doses of the two obesity drugs, making the advertisements misleading." Novo makes a parallel claim about the Mounjaro campaign — 15 mg Mounjaro compared against 1 mg Ozempic rather than the 2 mg maintenance dose. Lilly "denied the allegations on Tuesday and said it stands by its advertising, adding that it intends to vigorously defend itself." Korean coverage (Chosun Ilbo English, Sept 28) adds that Novo moved to suit only after Lilly rejected an April formal notice demanding it stop and revise the ads.
Stakes context from the same coverage: MorningStar estimates the global GLP-1 market at $200B by 2035 with Lilly capturing ~$120B — the advertising war is a fight over the direct-to-consumer narrative while Lilly compounds a lead (Zepbound ~802K weekly scripts vs all-Wegovy ~493K per the Oct 16 tracker, see Foundayo Clears EMA's CHMP for Weight Management AND Type 2 Diabetes — a Broader EU Label Than the Wegovy Pill's).
Status as of Oct 19: no preliminary-injunction ruling has been reported; the watch on the PI motion remains open.
Meaning: this is the first open legal front between the two incumbents of the obesity market. An injunction forcing Lilly to soften comparative claims would land on top of its Oct 29 Q3 print and Novo's Jan 1 price cut — a timing squeeze Lilly would feel in its most visible marketing channel.
-
An instance of In a saturated drug market, head-to-head superiority is manufactured by comparator selection. — Superiority manufactured from favorable dose comparisons is now being litigated as false advertising, exactly the comparator war the theme predicts. ↩︎